证券代码：600267 证券简称：海正药业 公告编号：临 2025-54 号 浙江海正药业股份有限公司 关于替加环素原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量 管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称 "EDQM"）签发的替加环素原料药欧洲药典适用性认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP 证书"）， 现就相关情况公告如下： 一、CEP证书相关信息 特此公告。 生产地址：浙江省台州市椒江区外沙路46号 发证机构：欧洲药品质量管理局（EDQM） 二、药品的其他相关情况 替加环素主要适用于18岁以上患者在下列情况下由特定细菌的敏感菌株所 致感染的治疗：复杂性腹腔内感染、复杂性皮肤和皮肤软组织感染、社区获得性 细菌 ...

Core Viewpoint - The company, Haizheng Pharmaceutical, has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP certificate) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Tigecycline active pharmaceutical ingredient [1] Group 1 - The CEP certificate indicates that Tigecycline is suitable for use in treating infections caused by specific sensitive strains of bacteria in patients aged 18 and above [1] - Tigecycline is primarily indicated for the treatment of complex intra-abdominal infections, complex skin and soft tissue infections, and community-acquired bacterial pneumonia [1]

Core Viewpoint - Haizheng Pharmaceutical has received the CEP certificate for Tigecycline raw materials from the European Medicines Agency, marking it as the first domestic company to achieve this certification, which enhances its qualifications for entering the EU and other markets that recognize the CEP certificate [1] Group 1 - The receipt of the CEP certificate signifies recognition and affirmation of the quality of the raw material by the European regulatory market [1] - This certification allows the company to expand its international market presence positively [1]

Core Viewpoint - The company has received the CEP certificate for tigecycline active pharmaceutical ingredient from the European Directorate for the Quality of Medicines and HealthCare (EDQM), marking a significant achievement as the first domestic enterprise to obtain this certification [1] Group 1 - The global sales volume of tigecycline active pharmaceutical ingredient is approximately 290.22 kilograms for the period from January to June 2025 [1]

Group 1 - The company, Haizheng Pharmaceutical, disclosed information regarding its share repurchase account in the section "Top Ten Shareholders and Share Repurchase Account Status" of its 2025 semi-annual report format [1]

Core Insights - The company emphasizes that research and development (R&D) is the core driving force for its growth, aiming for precise and efficient R&D [1] - The company focuses on key therapeutic areas such as cardiovascular and metabolic diseases, establishing a systematic layout for global patent barrier innovation pipelines [1] - The self-developed Class 1 small molecule innovative drug HS387 has received clinical implied approval from NMPA, officially entering the clinical development stage [1] - The company is accelerating the introduction of clinical-stage pipelines to enrich its product lineup and address more unmet clinical needs [1]

北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2025 年第一次临时股东大会的 法 律 意 见 书 康达(杭州)股会字【2025】第 0027 号 二〇二五年九月 北京康达（杭州）律师事务所 海正药业 2025 年第一次临时股东大会法律意见书 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正药业股份有限 公司（下称"海正药业"或"公司"）委托，指派本所律师出席公司 2025 年第 一次临时股东大会（下称"本次股东大会"）。根据《中华人民共和国公司法》 （下称"《公司法》"）、《中华人民共和国证券法》（下称"《证券法》"）、 《律师事 ...

证券代码：600267 证券简称：海正药业 公告编号：临2025-53号 浙江海正药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 10 日 (二)股东大会召开的地点：浙江海正药业股份有限公司会议室（台州市椒江区外 沙路 46 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 677 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 493,100,047 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 42.3940 | (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关于取消监事会并修订《公司章程》的议案 审议结果：通过 表决情况： 注：截至本次股东 ...

Investment Rating - The report maintains a "Buy" rating for the company based on its stable growth in traditional businesses and accelerated new business development [4][9]. Core Insights - In the first half of 2025, the company achieved a revenue of 5.25 billion yuan, a slight increase of 0.13%, while the net profit attributable to shareholders was 299 million yuan, a decrease of 31.29%. The non-recurring net profit improved significantly to 321 million yuan, reflecting a growth of 23.92% [1][4]. - The operating cash flow showed a substantial improvement, reaching 1.211 billion yuan, an increase of 54.98%. The gross margin was 43.94%, up by 4.57 percentage points, while the net margin decreased to 5.81%, down by 2.47 percentage points [1][4]. - The company has optimized its sales system, with a significant increase in its formulation business, achieving over 30% growth in sales revenue in the first half of 2025. The core product, Haibomai Tablets, also saw a sales growth exceeding 30% [1][2]. Financial Performance Summary - Revenue projections for 2025-2027 are estimated at 11.728 billion yuan, 13.039 billion yuan, and 14.383 billion yuan, representing year-on-year growth rates of 13.4%, 11.2%, and 10.3% respectively [2][8]. - The net profit attributable to shareholders is forecasted to be 707 million yuan, 842 million yuan, and 994 million yuan for the same period, with growth rates of 17.6%, 19.0%, and 18.1% respectively [2][8]. - The earnings per share (EPS) is expected to increase from 0.59 yuan in 2025 to 0.83 yuan in 2027, with a corresponding decrease in the price-to-earnings (P/E) ratio from 18.0 to 12.8 [2][8].

Industry Overview - The 27th Asia Pet Expo attracted over 510,000 visitors, showcasing the robust growth of China's pet economy, with a market size projected to reach 811.4 billion yuan by 2025, growing at a compound annual growth rate (CAGR) of 25.4% from 2015 to 2023 [1] - The pet-related business market in China has expanded from 97.8 billion yuan in 2015 to 592.8 billion yuan in 2023, indicating a significant upward trend [1] Company Performance - The pet sector achieved revenue of 6.381 billion yuan in the first half of 2025, a year-on-year increase of 22.03%, with net profit reaching 660 million yuan, up 20.28% [1] - Leading company Guobao Pet reported revenue of 3.221 billion yuan and net profit of 378 million yuan, with growth rates of 32.72% and 22.55% respectively [2] - Zhongchong Co. followed closely with revenue of 2.432 billion yuan and net profit of 203 million yuan, marking a 42.56% increase in net profit, the highest in the industry [2] - Petty Co. experienced a decline in both revenue and net profit, reporting 728 million yuan and 79 million yuan, down 13.94% and 19.23% respectively, attributed to U.S. tariff policies affecting overseas orders [3] - Lusi Co. reported an 11.32% increase in revenue to 391 million yuan but a 12.07% decrease in net profit to 30.46 million yuan due to falling product prices [3] Market Trends - The pet economy is driven by a generational shift in consumer attitudes, with younger generations (90s and 00s) becoming the primary pet owners, leading to a growing "it economy" around pets [5] - The pet food market holds a 52.8% share, followed by pet medical services at 28.0%, with increasing penetration rates in pet diagnosis, training, insurance, and travel [5] - The average cost of pet medical services is rising due to advancements in medical technology and diversified drug supply [5] Regulatory Environment - Recent policies from the Ministry of Agriculture and Rural Affairs and the State Administration for Market Regulation have focused on establishing standards for the pet industry [6] - Local governments are incorporating pet industry development into their plans, with initiatives aimed at promoting collaboration across various sectors [6] Investment Activity - The pet industry has seen 634 financing events as of the first quarter of 2025, with online platforms being the most active [6] - The pet economy concept index has risen by 43.21% year-to-date, indicating strong interest from the capital market [7]